Keywords: Biogen Idec, Multiple sclerosis, DR6 antagonist, Remyelination

Novel approach for multiple sclerosis treatment identified by Biogen Idec

Article | 04 July 2011

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) has revealed results from a study that suggest that inhibiting death receptor-6 (DR6) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in